Evidence map›Paper›PMID 38582094›Full record

ArticleLancet (London, England)2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

GBD 2021 Causes of Death Collaborators

Erratum issued 5 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Lancet (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 5 registered trials, which are not on this map. Cited by 1,919 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,919citing papers in PubMed, 6 pooled it
707.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06707441 recruitingnot on this mapstarted 2025, after this paper: background citation

Which Score Best Predicts Outcomes in Chest Trauma? A Prospective Comparison of Thorax and Trauma Injury Severity Scores

TypeobservationalSponsorAl-Nahrain UniversityRan2025 to 2026Enrolled150ConditionsChest Trauma
NCT06839586 phase1 / phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of CMTS4520 for Chronic Diarrhoea in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2025 to 2030Enrolled100ConditionsDiarrhoeaArmsCMTS4520 (dietary fiber and probiotics), Placebo
NCT06839599 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults: a Randomized, Double-Blind, Placebo-Controlled Trial.

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2025 to 2030Enrolled100ConditionsDiarrheaArmsCMTS4520 (dietary fiber probiotics), Placebo
NCT07280988 naactive not recruitingnot on this mapstarted 2025, after this paper: background citation

The Effect of Environment Specific Slip Resistant Footwear - A Randomized Cross-Over Study From Danish Dairy Industry

TypeinterventionalSponsorAalborg UniversityRan2025 to 2025Enrolled22ConditionsSlips, Falls Prevention, Perceived SlipperinessArmsEnvironment specific safety footwear
NCT07767370 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomised, Controlled, Double-blind Exploratory Study of ND-12 Combined With H-6 in the Treatment of Adult Chronic Inflammatory Diarrhea

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2026 to 2028Enrolled36ConditionsDiarrhea Chronic, UC - Ulcerative ColitisArmsmesalazine, ND-12, ND-12/H-6
3 · Its place in the literature

Who cites it

1,919 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,245 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Burden of Gastric Cancer in China from 1990 to 2023.Public health in practice (Oxford, England) · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,859 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 2 institutions in 2 countries.

GBD 2021 Causes of Death Collaborators
University of Washington · USSorbonne Université · FR

Funding

Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
ACADEMIC PEDIATRIC INFECTIOUS DISEASET32HD007233 · NICHD · SEATTLE CHILDREN'S HOSPITAL · PI KEVIN B URDAHL · 1985 to 2026
$6.7M
Examining Intensive Outpatient Programs as a Potential Mechanism to Reduce Suicide Risk During the Post-Hospitalization Period Among Medicaid RecipientsR01MH131528 · NIMH · YALE UNIVERSITY · PI Taeho Gregory Rhee, SAMUEL WILKINSON · 2023 to 2026
$2.6M
Longitudinal Associations of Electroconvulsive Therapy with Neuropsychiatric Symptoms, Geriatric Syndromes, and Nursing Home Admission and Mortality Rates among Adults with DementiaR01AG080647 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI RHEE, TAEHO GREGORY · 2023 to 2025
$1.0M
Implementation research for comprehensive cardiometabolic care in GuatemalaK23HL161271 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Clifford Flood · 2022 to 2026
$949k
Impact of cannabis legalization on prescription drug use and health outcomes in ConnecticutR21DA057540 · NIDA · YALE UNIVERSITY · PI RADHAKRISHNAN, RAJIV, RHEE, TAEHO GREGORY · 2023 to 2024
$475k
Associations of Opioid Prescribing with Long-term Functional Outcomes and Mortality Rates in Older Nursing Home ResidentsR21AG070666 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI RHEE, TAEHO GREGORY · 2021 to 2022
$295k
Epidemiology and Clinical Outcomes of Electroconvulsive Therapy Use in Nursing Home Residents with DementiaR21AG078972 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI RHEE, TAEHO GREGORY · 2023 to 2024
$294k
Medical Research CouncilNHLBI NIH HHS K23 HL161271NIA NIH HHS P30 AG024824NIA NIH HHS R01 AG080647NIA NIH HHS R21 AG070666NIA NIH HHS R21 AG078972NICHD NIH HHS T32 HD007233NIDA NIH HHS R21 DA057540NIMH NIH HHS R01 MH131528Wellcome Trust
6 · The paper itself

Abstract

backgroundRegular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations.

methodsThe Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds.

findingsThe leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles.

interpretationLong-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere.

fundingBill & Melinda Gates Foundation.

Indexed as

Cause of DeathCOVID-19Global Burden of DiseaseGlobal HealthLife ExpectancyAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansInfantInfant, NewbornMale

Identifiers

PMID38582094
PMCPMC11126520
OpenAlexW4393858312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.